ACR Appropriateness Criteria radiologic management of hepatic malignancy.

Management of hepatic malignancy is a challenging clinical problem involving several different medical and surgical disciplines. Because of the wide variety of potential therapies, treatment protocols for various malignancies continue to evolve. Consequently, development of appropriate therapeutic algorithms necessitates consideration of medical options, such as systemic chemotherapy; surgical options, such as resection or transplantation; and locoregional therapies, such as thermal ablation and transarterial embolization. The authors discuss treatment strategies for the 3 most common subtypes of hepatic malignancy treated with locoregional therapies: hepatocellular carcinoma, neuroendocrine metastases, and colorectal metastases. The ACR Appropriateness Criteria(®) are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

[1]  D. Nagorney,et al.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. , 2003, Journal of the American College of Surgeons.

[2]  Joong-Won Park,et al.  Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. , 2012, Journal of hepatology.

[3]  R. Salem,et al.  Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies , 2012, Current Treatment Options in Oncology.

[4]  G. Dodd,et al.  Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. , 2001, AJR. American journal of roentgenology.

[5]  J. Charboneau,et al.  Treatment of Neuroendocrine Cancer Metastatic to the Liver: The Role of Ablative Techniques , 2005, CardioVascular and Interventional Radiology.

[6]  A. Benson,et al.  Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature , 1998, Cancer.

[7]  W. Lau,et al.  Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. , 2007, Radiology.

[8]  M. Valsecchi,et al.  Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  G. Gores,et al.  Liver transplantation for cholangiocarcinoma , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  Minshan Chen,et al.  A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma , 2009, Journal of Cancer Research and Clinical Oncology.

[11]  Yong Zeng,et al.  A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.

[12]  Kurinchi Gurusamy,et al.  Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. , 2010, Journal of hepatology.

[13]  H. Pitt,et al.  Hepatic Neuroendocrine Metastases: Chemo- or Bland Embolization? , 2008, Journal of Gastrointestinal Surgery.

[14]  Angelo Andriulli,et al.  Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials , 2009, The American Journal of Gastroenterology.

[15]  M. Ychou,et al.  Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  V. Mazzaferro,et al.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. , 2011, Cancer treatment reviews.

[17]  K. Delman,et al.  Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. , 2010, Journal of vascular and interventional radiology : JVIR.

[18]  M. Reiser,et al.  Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival , 2012, CardioVascular and Interventional Radiology.

[19]  N. Pavlakis,et al.  Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis , 2009, Journal of clinical gastroenterology.

[20]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[21]  Hongyu Zhou,et al.  Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. , 2013, Hepato-gastroenterology.

[22]  K. Brown,et al.  Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. , 2008, Journal of vascular and interventional radiology : JVIR.

[23]  Luigi Solbiati,et al.  Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? , 2007, Hepatology.

[24]  J. Gibbs,et al.  Regional treatment of colorectal liver metastasis , 2010, Journal of surgical oncology.

[25]  H-X Xu,et al.  Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. , 2011, The British journal of radiology.

[26]  M. Barone,et al.  Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. , 2003, Hepato-gastroenterology.

[27]  Robert C. G. Martin,et al.  Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. , 2012, Hepato-gastroenterology.

[28]  T. de Baère,et al.  Strategies for resection using portal vein embolization: metastatic liver cancer. , 2008, Seminars in interventional radiology.

[29]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[30]  R. J. Haas,et al.  Bringing unresectable liver disease to resection with curative intent. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[32]  C. Meyer,et al.  Liver transplantation for cholangiocarcinoma: results in 207 patients. , 2000, Transplantation.

[33]  S. Zangan,et al.  Chemoembolization for hepatocellular carcinoma. , 2011, Seminars in roentgenology.

[34]  Y. Shin,et al.  Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. , 2013, Radiology.

[35]  W. Lees,et al.  Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. , 2008, Journal of vascular and interventional radiology : JVIR.

[36]  D. Geller,et al.  Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation , 2008, Annals of Surgical Oncology.

[37]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[38]  J. Furui,et al.  A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. , 2002, Surgery.

[39]  M. Manns,et al.  Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. , 2002, Transplantation.

[40]  Cynthia S. Johnson,et al.  Stereotactic body radiotherapy for primary hepatocellular carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[41]  J. Dancey,et al.  Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. , 2005, Journal of vascular and interventional radiology : JVIR.

[42]  J. Geoghegan,et al.  Treatment of colorectal liver metastases , 1999, The British journal of surgery.

[43]  A. Benson,et al.  Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres , 2009, Cancer.

[44]  T. Pfammatter,et al.  Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence‐Based Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[45]  Thomas J Vogl,et al.  Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. , 2009, European journal of radiology.

[46]  T. Pawlik,et al.  Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[48]  T. Chua,et al.  Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option , 2010, Annals of surgical oncology.

[49]  L. Ellis,et al.  Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis , 2005, Annals of Surgical Oncology.

[50]  P. Somasundar,et al.  Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. , 2010, Surgical oncology.

[51]  S. Curley,et al.  High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Christopher L Brace,et al.  Microwave Ablation of Hepatic Malignancy , 2013, Seminars in Interventional Radiology.

[53]  F. Xia,et al.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. , 2012, Journal of hepatology.

[54]  S. Stavropoulos,et al.  Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. , 2007, Journal of vascular and interventional radiology : JVIR.

[55]  I. Kamel,et al.  Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. , 2009, Journal of vascular and interventional radiology : JVIR.

[56]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[57]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[59]  R. Schilsky,et al.  Recommendations for management of patients with neuroendocrine liver metastases. , 2014, The Lancet. Oncology.

[60]  P. Kim,et al.  Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. , 2011, AJR. American journal of roentgenology.

[61]  Carlo Bartolozzi,et al.  Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. , 2005, Radiology.

[62]  W. Lau,et al.  The Current Role of Radiofrequency Ablation in the Management of Hepatocellular Carcinoma: A Systematic Review , 2009, Annals of surgery.

[63]  N. Kemeny,et al.  Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. , 2010, Seminars in oncology.

[64]  W. Lau,et al.  Percutaneous thermal ablation of medium and large hepatocellular carcinoma , 2009, Cancer.

[65]  M. Guba,et al.  Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[66]  Hongzan Sun,et al.  Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials , 2013, European journal of gastroenterology & hepatology.

[67]  M. Talamonti,et al.  Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. PART I: Diagnosis‐clinical staging and pathology , 2012, Journal of surgical oncology.

[68]  M. Milas,et al.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. , 2007, Surgery.

[69]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.

[70]  A. Tsung,et al.  Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[71]  M. Feng,et al.  Radiation therapy for hepatocellular carcinoma. , 2011, Seminars in radiation oncology.

[72]  I. Modlin,et al.  article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .

[73]  W. Lees,et al.  Radiofrequency ablation of neuroendocrine liver metastases—the Middlesex experience , 2005, Abdominal Imaging.

[74]  C. Georgiades,et al.  Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. , 2005, Journal of vascular and interventional radiology : JVIR.

[75]  L. Berk,et al.  Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. , 2010, Cancer control : journal of the Moffitt Cancer Center.

[76]  E. Vicaut,et al.  Radiofrequency ablation of hepatocellular carcinoma: Long‐term results and prognostic factors in 235 Western patients with cirrhosis , 2009, Hepatology.

[77]  A. Benson,et al.  Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. , 2013, Journal of vascular and interventional radiology : JVIR.

[78]  K. Öberg,et al.  Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  L. Schwartz,et al.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  R. Dhanasekaran,et al.  Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) , 2010, Journal of surgical oncology.

[81]  K. Ahrar,et al.  Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors , 2005, Cancer.

[82]  R. Arnold,et al.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. , 1996, Gut.

[83]  Kenneth G. Thurston,et al.  Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. , 2004, Journal of vascular and interventional radiology : JVIR.

[84]  M. Roček,et al.  Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study , 2010, Annals of Surgical Oncology.

[85]  C. Hammill,et al.  Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis. , 2011, Archives of surgery.

[86]  G. Klintmalm,et al.  Long‐term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[87]  Ming Shi,et al.  Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. , 2012, Radiology.

[88]  A. Cucchetti,et al.  Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. , 2013, Journal of hepatology.

[89]  G. Gores,et al.  Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[90]  J. Trojan,et al.  Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success , 2012, International journal of cancer.

[91]  Ding‐Shinn Chen,et al.  Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma: A Prospective Study , 2005, Annals of surgery.

[92]  T. Vogl,et al.  Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. , 2009, European journal of radiology.

[93]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[94]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  T. Pawlik,et al.  Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury , 2013, CardioVascular and Interventional Radiology.

[96]  W. Lau,et al.  A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.

[97]  K. Ahrar,et al.  Update on the management of neuroendocrine hepatic metastases. , 2006, Journal of vascular and interventional radiology : JVIR.

[98]  M. Soulen,et al.  Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. , 2004, Gastroenterology.

[99]  J. Primrose,et al.  Surgery for colorectal liver metastases , 2010 .

[100]  N. Nicolay,et al.  Liver metastases from colorectal cancer: radioembolization with systemic therapy , 2009, Nature Reviews Clinical Oncology.

[101]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[102]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[103]  D. Breen,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) , 2005, Gut.

[104]  H. Blum,et al.  Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy , 2012, European journal of gastroenterology & hepatology.

[105]  G. Gores,et al.  Drop‐out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[106]  A. Benson,et al.  Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. , 2001, Surgery.

[107]  E. Wolin The expanding role of somatostatin analogs in the management of neuroendocrine tumors. , 2012, Gastrointestinal cancer research : GCR.

[108]  Junji Konishi,et al.  Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. , 2002, Radiology.

[109]  M. Abecassis,et al.  Yttrium‐90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation , 2006, Journal of surgical oncology.

[110]  M. Abecassis,et al.  A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[111]  Bruno Sangro,et al.  Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives , 2013, Hepatology.

[112]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[113]  T. Chua,et al.  Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[114]  E. Abdalla Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome , 2010, Journal of surgical oncology.

[115]  T. de Baère,et al.  Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. , 2012, Journal of hepatology.

[116]  K. Herfarth,et al.  Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution , 2013, Radiation oncology.

[117]  G. M. Briggs,et al.  Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  C. Bartolozzi,et al.  Percutaneous Radiofrequency Ablation of Hepatic Colorectal Metastases: Technique, Indications, Results, and New Promises , 2004, Investigative radiology.

[119]  H. Rhim,et al.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.

[120]  Herb Chen,et al.  Metastatic neuroendocrine hepatic tumors: resection improves survival. , 2006, Archives of surgery.

[121]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[122]  J. Geschwind,et al.  Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand? , 2010, Annals of Surgical Oncology.

[123]  K. Thorlund,et al.  Cryotherapy for hepatocellular carcinoma. , 2009, The Cochrane database of systematic reviews.

[124]  N. Obuchowski,et al.  Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.

[125]  T. Therneau,et al.  Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma , 2013, CardioVascular and Interventional Radiology.

[126]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[127]  H. Takaki,et al.  Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. , 2013, Journal of vascular and interventional radiology : JVIR.

[128]  R. Branch,et al.  Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma , 2010, Cancer.

[129]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[130]  W. Chapman,et al.  Radiofrequency ablation for resectable colorectal hepatic metastases: is it time for a randomized controlled trial? , 2010, Annals of surgery.

[131]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[132]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[133]  D. Morris,et al.  Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases , 2008, Cancer.

[134]  Kenneth G. Thurston,et al.  Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. , 2005, Journal of vascular and interventional radiology : JVIR.

[135]  M. Ducreux,et al.  Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure , 2007, Annals of Surgical Oncology.

[136]  W. Chapman,et al.  Outcomes of Neoadjuvant Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Before Liver Transplantation , 2008, Annals of surgery.

[137]  K. Togashi,et al.  Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? , 2009, Radiology.

[138]  E. Abdalla,et al.  Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. , 2005, Journal of vascular and interventional radiology : JVIR.

[139]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[140]  Y. Maehara,et al.  Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience. , 2007, Journal of the American College of Surgeons.